Mingxi Li, Ph.D.

Dr. Mingxi Li is an investor and entrepreneur specializes in identifying and commercializing early-stage life science innovation, with extensive experiences in cross-border investments and project incubation. Dr. Li is the partner of GT Healthcare Capital Partners and the CEO of Apeiron Therapeutics, he has a deep understanding of the Chinese and global healthcare industry and […]

Fred Aswad, J.D., Ph.D.

Dr. Fred Aswad is the Senior Vice President of Biology at Apeiron Therapeutics. He has over 15 years of research and development experience in the biotechnology industry. He began his career at Bayer, where he played a leadership role in developing the immuno-oncology portfolio and development of novel drug discovery platforms. After Bayer, he went […]

Xiaohui Gu, Ph.D.

Dr. Xiao-hui Gu is the Senior Vice President of Chemistry at Apeiron Therapeutics. Dr. Gu has over 20 years research and development experience in the pharmaceutical industry. Dr. Gu has been engaged in the research, development and management of novel drugs at several pharmaceutical companies and CROs, including X-Ceptor, Exelixis, ShangPharma, Otsuka and Pharmaron. Prior […]

Jim Joseph, Ph.D.

Dr. Jim Joseph is the Executive Director of Biology at Apeiron Therapeutics. He has over 15 years of small molecule oncology drug discovery experience leading research teams supporting preclinical activities ranging from new target identification and validation to translational biology supporting ongoing clinical trials. Most recently Jim was an Associate Director at Ideaya Biosciences where […]

Yisong Xiao, Ph.D.

Dr. Yisong Xiao is the Senior Director of Chemistry at Apeiron Therapeutics. He has over 18 years of research and development experience in the pharmaceutical industry. Dr. Xiao has worked on a wide array of novel small molecule drug discovery projects, including kinase inhibitors, ion channels, GPCRs and anti-viral therapeutics. He was also a member […]

Yanfeng Zhou

Yanfeng is the CMC Director at Apeiron Therapeutics. He has over 15 years experience in drug discovery and non-clinical development with a focus on CMC. Prior to joining Apeiron, he served as the R&D director at 2Y-Chem Co., LTD., where he made significant contributions and led several programs through the non-clinical development phase and into […]

Weifeng Mao, Ph.D.

Dr. Weifeng Mao is the Director of Biology at Apeiron Therapeutics. He has more than 18 years experience in the pharmaceutical industry. He has deep expertise in building and optimizing in vitro screening and characterization platforms to discover novel drugs. Prior to joining Apeiron, Dr. Mao worked at WuXi AppTec where he established several in […]

Minghua Wang, Ph.D.

Dr. Minghua Wang is the Director of AIDD at Apeiron Therapeutics. He has over 15 years of small molecule drug discovery experience. Minghua has worked at different biotech companies, applying computational chemistry to drug design in many drug targets, spanning from enzymes to receptors. Most recently he worked on membrane protein targets in neuroscience diseases […]

Lucy Yu

Lucy Yu is the Human Resources Director at Apeiron Therapeutics. She has over 14 years of human resources experience in the pharmaceutical and financial industry. Prior to joining Apeiron, Lucy worked for Sanofi, Citibank and AMS where she gained extensive experience in talent acquisition, organization development and talent development. Lucy received her Master degree of […]